SANUWAVE™ ANNOUNCES APPROVAL FOR DIABETIC FOOT ULCER TREATMENT

       SANUWAVE Inc (Alpharetta, Ga), a leading provider and developer of Pulsed Acoustic Cellular Expression (PACE^™) technology, announces the company has received conditional approval from the US Food and Drug Administration (FDA) to initiate a multicenter, prospective, randomized clinical trial utilizing its dermaPACE^™ device for the treatment of diabetic foot ulcers.

       The device produces stresses at a cellular level that leads to immediate increases in microcirculation and signals the cellular release of specific proteins. These proteins include angiogenic growth factors that have been clinically shown to support neovascularization.

       Visit http://www.sanuwave.com for more information.

THERMOGENESIS OBTAINS FDA CLEARANCE TO MARKET CRYOSEAL®

       ThermoGenesis Corp (Rancho Cordova, Calif), a developer and manufacturer of product platforms that enable the processing and cryopreservation of stem cells for regenerative medicine, as well as processing protein gels for surgical wound care, announces that the US Food and Drug Administration (FDA) has cleared the company’s CryoSeal^® FS System’s autologous fibrin sealant.

       The CryoSeal FS System is an automated device and companion sterile blood processing disposable used to prepare fibrin sealants from plasma within 1 hour. The system produces a second-generation surgical sealant, which produces 2 interactive protein component solutions from a patient’s plasma. When combined at the wound site, the 2 components form an adhesive gel that helps stop bleeding and bonds tissue.

       Visit http://www.thermogenesis.com for more information.

STRATUS PHARMACEUTICALS ENTERS 3-YEAR CONTRACT WITH NOVATION

       Stratus Pharmaceuticals Inc (Kendall, Fla), a minority certified pharmaceutical manufacturer, disclosed that it has been awarded a 3-year contract with Novation (Irving, Tex) for all Stratus products. Stratus offers products, such as the papain and urea debriding ointments, Kovia and Ziox.

       Stratus’ focus remains on direct promotion to dermatologists, wound care specialists, plastic surgeons, and podiatrists.

       Visit http://www.stratuspharmaceuticals.com for more information.

GAYMAR HELPS HOSPITALS IMPROVE HEALTHCARE PRACTICES THROUGH THE 5 MILLION LIVES CAMPAIGN

       The 5 Million Lives Campaign, sponsored by the Institute for Health Care Improvement (IHI,Cambridge, Mass), is setting out to change the way health care is administered in the United States by enlisting hospitals and healthcare professionals in a campaign to protect patients from incidents of medical harm. The IHI has recently outlined 12 interventions that, if addressed, can greatly reduce the morbidity and mortality rates in hospitals.

       Gaymar Industries (Orchard Park, NY) offers products that directly affect several of the interventions outlined by the IHI. These include the ability to prevent MRSA, reduce surgical complications, prevent pressure ulcers, and to prevent ventilator-associated pneumonia.

       Visit http://www.gaymar.com for more information.

INNOCOLL INC AND BOURNE PARTNERS ANNOUNCE JOINT VENTURE TO BUILD LEADING ADVANCED WOUND CARE BUSINESS

       Innocoll Inc (Ashburn, Va) and Bourne Partners (Charlotte, NC) recently announced the formation of CollMed Laboratories Inc (Charlotte, NC) to commercialize and develop 4 products for the advanced wound care segment in the United States.

       The company’s first product, CollaGUARD^™, is a bioactive dressing with silver used to treat dermal wounds with mild infection or that are at risk for infection. Other products in development are CollMed’s DermsaSIL^™, a collagen-synthetic polymer composite dressing for deep wounds that penetrate the middle or deepest dermal layers, and CM004, an anti-adhesion barrier for prevention of surgical adhesions in gastrointestinal and gynecologic procedures.

       Visit http://www.collmedlabs.com for more information.